Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis
Status:
Terminated
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
Myelofibrosis is the gradual replacement of bone marrow (place where most new blood cells are
produced) by fibrous tissue which reduces the body's ability to produce new blood cells and
results in the development of chronic anemia (low red blood cell count). One of the main
distinctions of myelofibrosis is "extramedullary hematopoiesis", the migration or traveling
of the blood-forming cells out of the bones to other parts of the body, such as the liver or
spleen, resulting in an enlarged spleen and liver.
There is not a standard treatment for myelofibrosis, therefore there is no medication that is
specifically used in the treatment of myelofibrosis. Bevacizumab (Avastin®) targets and stops
a growth factor in the body that helps produce the type of fibrous tissue that is gradually
replacing the bone marrow in the bones.
The purpose of this study is to find out how safe and effective bevacizumab is in treating
myelofibrosis. The investigators also wish to find out important biologic characteristics or
features of myelofibrosis (how it works and operates) during the time of study participation
through an additional correlative biomarker study (MPD-RC #107). The purpose of the biomarker
study is to understand the causes of MPD and to develop improved methods for the diagnosis
and treatment of these diseases, while the main study is trying to find out how well
bevacizumab will work in treating the disease.
Phase:
Phase 2
Details
Lead Sponsor:
Ronald Hoffman
Collaborators:
Myeloproliferative Disorders-Research Consortium National Cancer Institute (NCI)